PHILADELPHIA, March 27, 2023 Passage Bio, Inc. , a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced. | March 27, 2023
Precision BioSciences, Inc. a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will. | March 27, 2023
/PRNewswire/ The Sumaira Foundation (TSF), a nonprofit organization focused on the rare neuroimmune diseases of NMOSD and MOGAD, is pleased to announce.
/PRNewswire/ The Sumaira Foundation (TSF), a nonprofit organization focused on the rare neuroimmune diseases of NMOSD and MOGAD, is pleased to announce.